The use of generic biotech medicines could save Marylanders a reported $1.388 billion over a 10-year period and an estimated $71 billion across the U.S., according to a report issued by St. Louis-based Express Scripts, one of the largest pharmacy benefit management companies in North America and a major prescription plan provider in Maryland.
Key to this cost savings are both the enactment of the Access To Life-Saving Medicine Act of 2007, sponsored by Sen. Hillary Clinton, D-N.Y., and others, and the release of federal guidelines by the Food and Drug Administration for generic biotech medicines.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.